Abstract
A significant growth of bacterial resistance to antimicrobial agents has been reported globally over the past decades. Pneumococcus and Haemophilus influenzae are the major respiratory and ENT pathogens among children in the Russian Federation. To date, the problem of rational and effective bacterial respiratory tract infections therapy remains unsettled. The emergence of the new high-dose amoxicillin with clavulanate provides additional opportunities for respiratory disease therapy in children with risk factors for drug-resistant pathogens.
Key words: antimicrobial resistance, respiratory and ENT infections, children, antibacterial therapy, inhibitor-protected aminopenicillins, high-dose amoxicillin with clavulanate.
Key words: antimicrobial resistance, respiratory and ENT infections, children, antibacterial therapy, inhibitor-protected aminopenicillins, high-dose amoxicillin with clavulanate.
For citation:Lokshina E.E. New high-dose amoxicillin with clavulanate in therapy of acute respiratory and ENT infections in children . Clinical review for general practice. 2021; 1: 12–16. DOI: 10.47407/kr2021.2.1.00027
All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.
